Breast Cancer

- **Triple negative breast cancer (TNBC)**
  - Locally advanced/ metastatic TNBC

- **Hormone receptor positive (HR+)**
  - Locally advanced/ metastatic ER+ and/or PR+/HER2-
  - Locally advanced/ metastatic ER+/HER2-

- **Non HER2 positive with BRCA mutation**
  - PTEN or PIK3CB mutation (TNBC or ER+/HER2-)
  - With residual cancer burden (TNBC or ER+ and/or PR+, HER2- BC)

- **TNBC or HR+**

- **HER2 positive**
  - HER2+ PIK3CA mutation, PTEN mutation or PTEN loss

**ETCTN Trials by Disease/Treatment Area: Breast Cancer**

- **10020**: A Phase II Open-label, Randomized Study of PARP Inhibition (Olaparib) Either Alone or in Combination with Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2 Positive Breast Cancer

- **100146**: Randomized Phase 2 Clinical Trial of Nab-Paclitaxel + Durvalumab + Neoantigen Vaccine Vs. Nab-Paclitaxel + Durvalumab in Patients with Metastatic Triple Negative Breast Cancer

- **9881**: A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors (4 cohorts: NSCLC, TNBC, PDAC, SCLC)

- **10287**: A Randomized Phase I/II Trial of Fulvestrant and Abemaciclib in Combination with Copanlisib (FAC) Versus Fulvestrant and Abemaciclib Alone (FA) for Endocrine Resistant, Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer (FAC vs FA)

- **10195**: A Phase 2 Study of Copanlisib (BAY 80-6946) in Combination with Fulvestrant in Women with Metastatic Breast Cancer Progressing After Aromatase Inhibitor Plus CDK 4/6 Inhibitor

- **10302**: Phase II Trial of Radium-223 in Combination with Paclitaxel in Patients with Bone Metastatic Breast Cancer

- **10131**: A Phase I Study of AZD8186 in Combination with Docetaxel in Patients with PTEN Mutated or PIK3CB Mutated Advanced Solid Tumors, Potentially Amenable to Docetaxel (Dose escalation: Solid tumors with PTEN or PIK3CB Mutations; Expansion cohorts include: breast, prostate, and other solid tumors.)

- **10291**: A Phase Ib/II Trial of Copanlisib in Combination with Trastuzumab and Pertuzumab After Induction Treatment of HER2 Positive (HER2+) Metastatic Breast Cancer (MBC) with PIK3CA Mutation or PTEN Mutation (Limited in phase 1 only; will open ETCTN-wide in phase 2).

- **10382**: A Phase I/II Trial Evaluating the Safety and Efficacy of Eribulin in Combination with Copanlisib in Patients with Metastatic Triple Negative Breast Cancer

- **9844**: A Phase 1 Study Evaluating Safety, Tolerability, and Preliminary Antitumor Activity of Entinostat and Nivolumab with or Without Ipilimumab in Advanced Solid Tumors

- **10296**: Phase Ib/II Trial of Copanlisib in Combination with Trastuzumab and Pertuzumab After Induction Treatment of HER2 Positive (HER2+) Metastatic Breast Cancer (MBC) with PIK3CA Mutation or PTEN Mutation (Limited in phase 1 only; will open ETCTN-wide in phase 2).

**NOTE:** *No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: December 16, 2019